Cardiovascular risks of atypical antipsychotic drug treatment

Milou Daniel Drici, Silvia Priori

Research output: Contribution to journalArticlepeer-review


Atypical antipsychotics are the treatment of choice for patients with schizophrenia. They are generally better tolerated than conventional antipsychotics since most do not cause debilitating extrapyramidal symptoms. They are associated though with an array of cardiovascular adverse events that may affect morbid-mortality of schizophrenic patients. Orthostatic hypotension, electrocardiographic changes and metabolic syndrome (MS) are the main cardiovascular effects of atypical antipsychotics. They contribute to the overall disease burden associated with schizophrenia even though the benefit risk of such treatments still is highly favourable. We aim to review the main cardiovascular side effects of new atypical oral antipsychotics, the pharmacological mechanisms involved, and to which drugs they are particularly attributed.

Original languageEnglish
Pages (from-to)882-890
Number of pages9
JournalPharmacoepidemiology and Drug Safety
Issue number8
Publication statusPublished - Aug 2007


  • Antipsychotic drugs
  • Cardiac risk
  • Cardiovascular disease
  • Metabolic syndrome
  • Schizophrenia
  • Sudden cardiac death

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Cardiovascular risks of atypical antipsychotic drug treatment'. Together they form a unique fingerprint.

Cite this